Chemclin Diagnostics Co. Ltd. A (SHG:688468) — Market Cap & Net Worth
Market Cap & Net Worth: Chemclin Diagnostics Co. Ltd. A (688468)
Chemclin Diagnostics Co. Ltd. A (SHG:688468) has a market capitalization of $354.52 Million (CN¥2.42 Billion) as of June 17, 2026. Listed on the SHG stock exchange, this China-based company holds position #14172 globally and #4262 in its home market, demonstrating a -3.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chemclin Diagnostics Co. Ltd. A's stock price CN¥6.04 by its total outstanding shares 401108000 (401.11 Million). Review 688468 current and long-term liabilities to assess the company's total debt and financial obligations.
Chemclin Diagnostics Co. Ltd. A Market Cap History: 2021 to 2026
Chemclin Diagnostics Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $987.99 Million to $354.52 Million (-23.00% CAGR).
Chemclin Diagnostics Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chemclin Diagnostics Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.30x
Chemclin Diagnostics Co. Ltd. A's market cap is 1.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.70x
Chemclin Diagnostics Co. Ltd. A's market cap is 9.70 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $987.99 Million | $470.77 Million | $142.76 Million | 2.10x | 6.92x |
| 2022 | $529.16 Million | $465.27 Million | $152.63 Million | 1.14x | 3.47x |
| 2023 | $621.61 Million | $445.34 Million | $147.37 Million | 1.40x | 4.22x |
| 2024 | $402.06 Million | $436.29 Million | $127.07 Million | 0.92x | 3.16x |
| 2025 | $430.82 Million | $332.68 Million | $44.41 Million | 1.30x | 9.70x |
Competitor Companies of 688468 by Market Capitalization
Companies near Chemclin Diagnostics Co. Ltd. A in the global market cap rankings as of June 17, 2026.
Key companies related to Chemclin Diagnostics Co. Ltd. A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #127 globally with a market cap of $177.98 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #181 globally with a market cap of $127.92 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #622 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #662 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #127 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.98 Billion | $473.72 |
| #181 | Danaher Corporation | NYSE:DHR | $127.92 Billion | $181.10 |
| #622 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $570.00 |
| #662 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Chemclin Diagnostics Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Chemclin Diagnostics Co. Ltd. A's market cap moved from $987.99 Million to $ 354.52 Million, with a yearly change of -23.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥354.52 Million | -17.71% |
| 2025 | CN¥430.82 Million | +7.15% |
| 2024 | CN¥402.06 Million | -35.32% |
| 2023 | CN¥621.61 Million | +17.47% |
| 2022 | CN¥529.16 Million | -46.44% |
| 2021 | CN¥987.99 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Chemclin Diagnostics Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $354.52 Million USD |
| MoneyControl | $354.52 Million USD |
| MarketWatch | $354.52 Million USD |
| marketcap.company | $354.52 Million USD |
| Reuters | $354.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more